Park Ha Biological [PHH] vs Procter & Gamble [PG] Detailed Stock Comparison
Park Ha Biological
NASDAQ
Loading...
Procter & Gamble
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Park Ha Biological wins in 5 metrics, Procter & Gamble wins in 10 metrics, with 0 ties. Procter & Gamble appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Park Ha Biological | Procter & Gamble | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 26.34 | 24.54 | Procter & Gamble |
| Price-to-Book Ratio | 3.08 | 7.30 | Park Ha Biological |
| Debt-to-Equity Ratio | 2.15 | 69.86 | Park Ha Biological |
| PEG Ratio | N/A | 21.53 | N/A |
| EV/EBITDA | -0.68 | 16.39 | Park Ha Biological |
| Profit Margin (TTM) | 91.80% | 18.95% | Park Ha Biological |
| Operating Margin (TTM) | -1,591.00% | 25.15% | Procter & Gamble |
| EBITDA Margin (TTM) | N/A | 25.15% | N/A |
| Return on Equity | -729.77% | 31.24% | Procter & Gamble |
| Return on Assets (TTM) | -298.12% | 10.91% | Procter & Gamble |
| Free Cash Flow (TTM) | $874,901 | $14.04B | Procter & Gamble |
| Dividend Yield | N/A | 1.92% | N/A |
| 1-Year Return | -89.19% | -8.87% | Procter & Gamble |
| Price-to-Sales Ratio (TTM) | 4.73 | 4.44 | Procter & Gamble |
| Enterprise Value | $12.93M | $400.90B | Procter & Gamble |
| EV/Revenue Ratio | 4.67 | 4.76 | Park Ha Biological |
| Gross Profit Margin (TTM) | N/A | 49.11% | N/A |
| Revenue per Share (TTM) | $0 | $36 | Procter & Gamble |
| Earnings per Share (Diluted) | $-0.72 | $6.51 | Procter & Gamble |
| Beta (Stock Volatility) | N/A | 0.36 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Park Ha Biological vs Procter & Gamble Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Park Ha Biological | -1.57% | -12.00% | -42.86% | -97.37% | -93.38% | -90.43% |
| Procter & Gamble | 0.52% | 1.90% | 6.32% | -1.71% | -8.36% | -3.59% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Park Ha Biological | -89.19% | -89.19% | -89.19% | -89.19% | -89.19% | -89.19% |
| Procter & Gamble | -8.87% | 14.33% | 15.84% | 133.88% | 164.93% | 181.23% |
Performance & Financial Health Analysis: Park Ha Biological vs Procter & Gamble
| Metric | PHH | PG |
|---|---|---|
| Market Information | ||
| Market Cap | $12.90M | $374.83B |
| Market Cap Category | Micro cap | Mega cap |
| 10 Day Avg. Volume | 942,316 | 5,263,346 |
| 90 Day Avg. Volume | 816,409 | 6,819,689 |
| Last Close | $0.44 | $160.02 |
| 52 Week Range | $0.43 - $41.49 | $149.91 - $180.43 |
| % from 52W High | -98.94% | -11.31% |
| All-Time High | $41.34 (Jul 08, 2025) | $180.43 (Nov 25, 2024) |
| % from All-Time High | -98.94% | -11.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.45% | 0.02% |
| Quarterly Earnings Growth | N/A | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.92% | 0.19% |
| Operating Margin (TTM) | -15.91% | 0.25% |
| Return on Equity (TTM) | -7.30% | 0.31% |
| Debt to Equity (MRQ) | 2.15 | 69.86 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.15 | $21.88 |
| Cash per Share (MRQ) | $0.05 | $4.08 |
| Operating Cash Flow (TTM) | $1.17M | $17.82B |
| Levered Free Cash Flow (TTM) | $5.11M | $11.38B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.92% |
| Last 12-Month Dividend | N/A | $3.03 |
Valuation & Enterprise Metrics Analysis: Park Ha Biological vs Procter & Gamble
| Metric | PHH | PG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 26.34 | 24.54 |
| Forward P/E | N/A | 21.53 |
| PEG Ratio | N/A | 21.53 |
| Price to Sales (TTM) | 4.73 | 4.44 |
| Price to Book (MRQ) | 3.08 | 7.30 |
| Market Capitalization | ||
| Market Capitalization | $12.90M | $374.83B |
| Enterprise Value | $12.93M | $400.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.67 | 4.76 |
| Enterprise to EBITDA | -0.68 | 16.39 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.36 |
| Book Value per Share (MRQ) | $0.15 | $21.88 |
Financial Statements Comparison: Park Ha Biological vs Procter & Gamble
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PHH | PG |
|---|---|---|
| Revenue/Sales | N/A | $20.89B |
| Cost of Goods Sold | N/A | $10.63B |
| Gross Profit | N/A | $10.26B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | $4.35B |
| EBITDA | N/A | $5.46B |
| Pre-Tax Income | N/A | $4.52B |
| Income Tax | N/A | $895.00M |
| Net Income (Profit) | N/A | $3.63B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PHH | PG |
|---|---|---|
| Cash & Equivalents | $547,498 | $9.56B |
| Total Current Assets | $2.84M | $25.39B |
| Total Current Liabilities | $1.52M | $36.06B |
| Long-Term Debt | $52,745 | $25.70B |
| Total Shareholders Equity | $1.51M | $52.28B |
| Retained Earnings | $271,788 | $129.97B |
| Property, Plant & Equipment | $70,739 | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PHH | PG |
|---|---|---|
| Operating Cash Flow | N/A | $3.71B |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $2.85B |
| Debt Repayment | N/A | $-1.05B |
| Common Stock Repurchase | N/A | $-1.35B |
Short Interest & Institutional Ownership Analysis
| Metric | PHH | PG |
|---|---|---|
| Shares Short | 1.02M | 16.72M |
| Short Ratio | 1.01 | 2.21 |
| Short % of Float | 0.10% | 0.01% |
| Average Daily Volume (10 Day) | 942,316 | 5,263,346 |
| Average Daily Volume (90 Day) | 816,409 | 6,819,689 |
| Shares Outstanding | 26.20M | 2.34B |
| Float Shares | 7.82M | 2.34B |
| % Held by Insiders | 0.73% | 0.00% |
| % Held by Institutions | 0.00% | 0.70% |
Dividend Analysis & Yield Comparison: Park Ha Biological vs Procter & Gamble
| Metric | PHH | PG |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.03 |
| Last 12-Month Dividend Yield | N/A | 1.92% |
| 3-Year Avg Annual Dividend | N/A | $3.51 |
| 3-Year Avg Dividend Yield | N/A | 0.63% |
| 3-Year Total Dividends | N/A | $10.53 |
| Ex-Dividend Date | N/A | Jan 24, 2025 |